Spatial molecular profiling of mixed invasive ductal and lobular breast cancers reveals heterogeneity in intrinsic molecular subtypes, oncogenic signatures, and mutations.
Humans
Female
Carcinoma, Lobular
/ genetics
Carcinoma, Ductal, Breast
/ genetics
Mutation
Breast Neoplasms
/ genetics
Cadherins
/ genetics
Gene Expression Regulation, Neoplastic
Biomarkers, Tumor
/ genetics
Triple Negative Breast Neoplasms
/ genetics
Transcriptome
Gene Expression Profiling
/ methods
breast cancer
mixed ductal–lobular carcinoma
single cell omics
spatial transcriptomics
tumor heterogeneity
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
30 Jul 2024
30 Jul 2024
Historique:
medline:
23
7
2024
pubmed:
23
7
2024
entrez:
23
7
2024
Statut:
ppublish
Résumé
Mixed invasive ductal and lobular carcinoma (MDLC) is a rare histologic subtype of breast cancer displaying both E-cadherin positive ductal and E-cadherin negative lobular morphologies within the same tumor, posing challenges with regard to anticipated clinical management. It remains unclear whether these distinct morphologies also have distinct biology and risk of recurrence. Our spatially resolved transcriptomic, genomic, and single-cell profiling revealed clinically significant differences between ductal and lobular tumor regions including distinct intrinsic subtype heterogeneity - e.g., MDLC with triple-negative breast cancer (TNBC) or basal ductal and estrogen receptor positive (ER+) luminal lobular regions, distinct enrichment of cell cycle arrest/senescence and oncogenic (ER and
Identifiants
pubmed: 39042692
doi: 10.1073/pnas.2322068121
doi:
Substances chimiques
Cadherins
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2322068121Subventions
Organisme : The Dynami Foundation
ID : xxxxxxxxxxxxxx
Organisme : Breast Cancer Research Foundation (BCRF)
ID : xxxxxxxxxxxxxx
Organisme : American Society of Clinical Oncology (ASCO)
ID : xxxxxxxxxxxxxx
Organisme : American Society of Clinical Oncology (ASCO)
ID : xxxxxxxxxxxxxx
Organisme : NCI NIH HHS
ID : P50 CA247749
Pays : United States
Déclaration de conflit d'intérêts
Competing interests statement:The authors declare no competing interest.